Astrazeneca PLC (AZN): The stock had negative money flow to the tune of ($1.7 million) on Thursday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $3.01 million, whereas, the outflow of money on downticks was $4.71 million and the ratio between the two was 0.64. The block trade had a negative net money flow of ($1.63 million). On the other hand, downticks amounted to $1.63 million of the traded value, which shows distribution in the stock by traders. Astrazeneca PLC (AZN) closed with marginal gains of 16 cents to end the day at $30.32, an increase of 0.53% over the previous days close. The stock recorded 0.7% for the week.
The stock has recorded a 20-day Moving Average of 3.94% and the 50-Day Moving Average is 4.52%. Shares have dropped -10.78% from its 1 Year high price. On Dec 1, 2015, the shares registered one year high at $34.88 and the one year low was seen on Jun 16, 2016. The 50-Day Moving Average price is $29.15 and the 200 Day Moving Average price is recorded at $29.73.
Astrazeneca PLC (NYSE:AZN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $30.48 and $30.16 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $30.50. The buying momentum continued till the end and the stock did not give up its gains. It closed at $30.34, notching a gain of 0.60% for the day. The total traded volume was 9,503,186 . The stock had closed at $30.16 on the previous day.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).